Bordetella pertussis infection: Pathogenesis, diagnosis, management, and the role of protective immunity

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 19, Issue 2, 2000, Pages 77-88

  Kerr, J R ^a   Matthews, R C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; AGGLUTININ; ANTIBIOTIC AGENT; ANTIBODY; AZITHROMYCIN; CLARITHROMYCIN; CYTOTOXIN; ERYTHROMYCIN; HEMAGGLUTININ; IMMUNOGLOBULIN; LIPOPOLYSACCHARIDE; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SERUM RESPONSE FACTOR; STEROID;

ANOREXIA; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; BRAIN DISEASE; FEVER; FIMBRIA; GENE CONTROL; HOST RESISTANCE; HUMAN; IMMUNITY; IMMUNIZATION; INFANT; MICROBIOLOGY; PAIN; PATHOGENESIS; PERTUSSIS; PRIORITY JOURNAL; REVIEW; SEROLOGY; VOMITING;

EID: 0034008433     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050435     Document Type: Review

References (104)

1. 1. Miller L, Vurdien IE, White JM: The epidemiology of pertussis in England and Wales. Communicable Disease Report Review (1992) 2:152-154
2. 2. Hewlett EL: Bordetella species. In: Principles and practice of infectious diseases. Mandell GL, Douglas RG Jr, Bennett JE (eds): Churchill Livingstone, New York (1995) pp 2078-2084
3. 3. Preston NW: Type-specific immunity against whooping cough. British Medical Journal (1963) 724-726
4. 4. Preston NW, Stanbridge TN: Efficacy of pertussis vaccines: a brighter horizon. British Medical Journal (1972) 3:448-451
5. 5. Stanbridge TN, Preston NW: Experimental pertussis infection in the marmoset: type-specificity of active immunity. Journal of Hygiene (1974) 72:213-228
6. 6. Sako W: Studies on pertussis immunisation. Journal of Pediatrics (1947) 30:29-40
7. 7. Miller JJ Jr, Silverberg RJ, Saito TM, Humber JB: An agglutinative reaction for Haemophilus pertussis II. Its relation to clinical immunity. Journal of Pediatrics (1943) 22:644-651
8. 8. Van Buynder PG, Owen D, Vurdien JE, Andrews NJ, Matthews RC, Miller E: Bordetella pertussis surveillance in England & Wales: 1995-1997. Epidemiology and Infection (1999) in press
9. 9. Preston NW, Zorgani AA, Carter EJ: Location of the three major agglutinogens of Bordetella pertussis by immunoelectronmicroscopy. Journal of Medical Microbiology (1990) 32:63-68
10. 10. Preston NW, Matthews RC: Acellular pertussis vaccines: progress but déja vu. Lancet (1998) 351:1811-1812
11. 11. Brennan MJ, Ming Li Z, Cowell JL, Bisher ME, Steven AC, Novotny P, Manclark CR: Identification of a 69 kDa nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infection and Immunity (1988) 56:3189-3195
12. 12. Meade BD, Lynn F, Reed GF, Mink CM, Romani TA, Deforest A, Deloria MA: Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell vaccines. Pediatrics (1995) 96:595-600
13. 13. Preston NW, Surapatana N, Carter EJ: A reappraisal of serotype factors 4, 5 and 6 of Bordetella pertussis. Journal of Hygiene (1982) 88:39-46
14. 14. Willems RJ, Geuijen C, van der Heide HG, Matheson M, Robinson A, Ebberink R, Theelen J, Mooi FR: Isolation of a putative fimbrial adhesin from Bordetella pertussis and the identification of its gene. Molecular Microbiology (1993) 9:623-634
15. 15. Willems RJ, van der Heide HG, Mooi FR: Characterisation of a Bordetella pertussis fimbrial gene cluster which is located directly downstream of the filamentous haemagglutinin gene. Molecular Microbiology (1992) 6:2661-2671
16. 16. Mooi FR, Jansen WH, Brunings H, Gielen H, van der Heide GH, Walvoort HC, Guinee PA: Construction and analysis of Bordetella pertussis mutants defective in the production of fimbriae. Microbial Pathogenesis (1992) 12:127-135
17. 17. Charles IG, Dougan G, Pickard D, Chatfield S, Smith M, Novotny P, Morrissey P, Fairweather NF: Molecular cloning and characterisation of protective outer membrane protein P.69 from Bordetella pertussis. Proceedings of the National Academy of Sciences of the USA (1989) 86:3554-3558
18. 18. Charles IG, Fairweather N, Pickard D, Beesley J, Anderson R, Dougan G, Roberts M: Expression of the Bordetella pertussis P.69 pertactin adhesin in Escherichia coli: fate of the carboxy-terminal domain. Microbiology (1994) 140:3301-3308
19. 19. Leininger E, Roberts M, Kenimer JG, Charles IG, Fairweather N, Novotny P, Brennan MJ: Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proceedings of the National Academy of Sciences of the USA (1991) 88:345-349
20. 20. Matthews RC, Preston NW: Bordetella. In: Emmerson AM, Hawkey PM, Gillespie SH (eds): Principles and practice of clinical bacteriology. Wiley, Chichester (1996) pp 323-336
21. 21. Pittman M: The concept of pertussis as a toxin-mediated disease. Pediatric Infectious Disease Journal (1984) 3:467-486
22. 22. Trollfors B, Taranger J, Lagergard T, Lind L, Sundh V, Zackrisson G, Lowe CU, Blackwelder W, Robbins JB: A double-blind, placebo-controlled trial of a monocomponent pertussis toxoid vaccine. New England Journal of Medicine (1995) 333:1045-1050
23. 23. Granström M, Olinder-Nielson AM, Holmblad P, Mark A, Hanngren K: Specific immunoglobulin for treatment of whooping cough. Lancet (1991) 338:1230-1233
24. 24. Katada T, Ui M: ADP ribosylation of the specific membrane protein of C6 cells by islet activating protein associated with modification of adenylate cyclase activity. Journal of Biological Chemistry (1982) 257:7210-7216
25. 25. Relman D, Tuomanen E, Falkow S, Golenbock DT, Saukkonen K, Wright SD: Recognition of a bacterial adhesin by an integrin: macrophage CR3 (alpha M beta 2, CD11b/ CD18) binds filamentous hemagglutinin of Bordetella pertussis. Cell (1990) 61:1375-1382
26. 26. Van't Wout J, Burnette WN, Mar WL, Rozdzinski E, Wright SD, Tuomanen EI: Role of carbohydrate recognition domains of pertussis toxin in adherence of Bordetella pertussis to human macrophages. Infection and Immunity (1992) 60:3303-3308
27. 27. Sato H, Sato Y: Protective activities in mice of monoclonal antibodies against pertussis toxin. Infection and Immunity (1990) 58:3369-3374
28. 28. Williamson P, Matthews RC: Development of neutralising human recombinant antibodies to pertussis toxin. FEMS Immunology and Medical Microbiology (1999) 23:313-319
29. 29. Ui M: The multiple biological activities of pertussis toxin. In: Wardlay AC, Parton R (eds): Pathogenesis and immunity in pertussis. Wiley, New York (1988) pp121-146
30. 30. Weiss AA, Hewlett EL: Virulence factors of Bordetella pertussis. Annual Reviews in Microbiology (1986) 40:661-666
31. 31. Cotter PA, Yuk MH, Mattoo S, Akerley BJ, Boschwitz J, Relman DA, Miller JF: Filamentous haemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonisation. Infection and Immunity (1998) 66:5921-5929
32. 32. Liu DF, Phillips E, Wizemann TM, Siegel MM, Tabei K, Cowell JL, Tuomanen E: Characterisation of a recombinant fragment that contains a carbohydrate recognition domain of the filamentous haemagglutinin. Infection and Immunity (1997) 65:3465-3468
33. 33. Wolff J, Coo GH, Goldhammer AR, Berkowitz SA: Calmodulin activates prokaryotic adenylate cyclase. Proceedings of the National Academy of Sciences of the USA (1980) 77:3841-3844
34. 34. Hanski E, Farfel Z: Bordetella pertussis invasive adenylate cyclase. Journal of Biological Chemistry (1985) 290:5526-5532
35. 35. Friedman R, Diederlein R, Glasser L, Galgiani J: Bordetella pertussis adenylate cyclase: effects of affinity-purified adenylate cyclase on human polymorphonuclear leukocyte functions. Infection and Immunity (1987) 55:135-140
36. 36. Glaser P, Sakamoto H, Bellalou J, Ullmann A, Danchin A: Secretion of cyclolysin, the calmodulin-sensitive adenylate cyclase-haemolysin bifunctional protein of Bordetella pertussis. EMBO Journal (1988) 7:3997-4004
37. 37. Gueirard P, Druilhe A, Pretolani M, Guiso N: Role of adenylate cyclase-haemolysin in alveolar macrophage apoptosis during Bordetella pertussis infection in vivo. Infection and Immunity (1998) 66:1718-1725
38. 38. Harvill ET, Cotter PA, Yuk MH, Miller JF: Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity. Infection and Immunity (1999) 67:1493-1500
39. 39. Goldman WE, Klapper DG, Baseman JB: Detection, isolation and analysis of a released Bordetella pertussis product toxic to cultured tracheal cells. Infection and Immunity (1982) 36:782-794
40. 40. Luker KE, Collier JL, Kolodziej EW, Marshall GR, Goldman WE: Bordetella pertussis tracheal cytotoxin and other muramyl peptides: distinct structure activity relationships for respiratory epithelial cytopathology. Proceedings of the National Academy of Sciences of the USA (1993) 90:2365-2369
41. 41. Livey I, Wardlaw AC: Production and properties of Bordetella pertussis heat labile toxin. Journal of Medical Microbiology (1984) 17:91-103
42. 42. Allen AG, Thomas RM, Cadisch JT, Maskell DJ: Molecular and functional analysis of the lipopolysaccharide biosynthesis locus wlb from Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Molecular Microbiology (1998) 29:27-38
43. 43. Finn TM, Stevens LA: Tracheal colonisation factor: a Bordetella pertussis secreted virulence determinant. Molecular Microbiology (1995) 16:625-634
44. 44. Fernandez RC, Weiss AA: Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infection and Immunity (1994) 62:4727-4738
45. 45. Kerr JR: Type III (contact-dependent) secretion in Gram-negative bacteria. Reviews in Medical Microbiology (1999) 10:155-164.
46. 46. Anderson DM, Schneewind O: A mRNA signal for the type III secretion of Yop proteins by Yersinia enterocolitica. Science (1997) 278:1140-1143
47. 47. Yuk MH, Harvill ET, Miller JF: The BvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica. Molecular Microbiology (1998) 28:945-959
48. 48. Kerr JR, Rigg GP, Matthews RC, Burnie JP: The BpeI locus encodes type III secretion machinery in Bordetella pertussis. Microbial Pathogenesis (1999) 27:349-367
49. 49. Cotter PA, Miller JF: BvgAS dependent phenotypic modulation of Bordetella species. In: Rappuoli R, Scarlato V, Arico B (eds): Signal transduction and bacterial virulence. RG Landes, Austin, TX (1995) pp 21-42
50. 50. Uhl MA, Miller JF: Central role of the BvgS receiver as a phosphorylated intermediate in a complex two-component phosphorelay. Journal of Biological Chemistry (1996) 271:33176-33180
51. 51. Uhl MA, Miller JF: Integration of multiple domains in a two-component sensor protein: the Bordetella pertussis BvgAS phosphorelay. EMBO Journal (1996) 15:1028-1036
52. 52. Masure HR: Modulation of adenylate cyclase toxin production as Bordetella pertussis enters human macrophages. Proceedings of the National Academy of Sciences of the USA (1992) 89:6521-6525
53. 53. Knapp S, Mekalanos JJ: Two trans-acting regulatory genes (vir and mod) control antigenic modulation in Bordetella pertussis. Journal of Bacteriology (1988) 170:5059-5066
54. 54. Stenson TH, Peppler MS: Identification of two Bvg-repressed surface proteins of Bordetella pertussis. Infection and Immunity (1995) 63:3780-3789
55. 55. Sandros J, Tuomanen E: Attachment factors of Bordetella pertussis: mimicry of eukaryotic cell recognition molecules. Trends in Microbiology (1993) 1:192-196
56. 56. Pittman M: Pertussis toxin: the cause of harmful effects and prolonged immunity of whooping cough: a hypothesis. Reviews in Infectious Diseases (1979) 1:401-412
57. 57. Cherry JD, Brunell PA, Golden GS, Karzon DT: Report of a Task Force on Pertussis and Pertussis Immunisation. Pediatrics (1988) 81:939-984
58. 58. Furman BL, Sidey FM, Smith M: Metabolic disturbances produced by pertussis toxin. In: Wardlaw AC, Parton R (eds): Pathogenesis and immunity in pertussis. Wiley, Chichester (1988) pp 147-172
59. 59. Kanai K: Japan's experience in pertussis epidemiology and vaccination in the past thirty years. Japanese Journal of Medical Science and Biology (1980) 33:107-143
60. 60. Cherry JD: The epidemiology of pertussis and pertussis immunisation in the United Kingdom and the United States: a comparative study. Current Problems in Pediatrics (1984) 14:1-78
61. 61. Romanus V, Jonsell R, Bergquist SO: Pertussis in Sweden after the cessation of general immunisation in 1979. Pediatric Infectious Disease Journal (1987) 6:364-371
62. 62. Anonymous: Seasonal rise in whooping cough. Communicable Disease Report (1997) 7:383-384
63. 63. Lambert HJ: Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Reports (1965) 80:365
64. 64. Isaacson J, Trollfors B, Taranger J, Zackrisson G, Lagergard T: How common is whooping cough in a nonvaccinating country? Pediatric Infectious Disease Journal (1993) 12:284-288
65. 65. Preston NW: Pertussis today. In: Wardlaw AC, Parton R (eds): Pathogenesis and immunity in pertussis. John Wiley, London (1988) pp 1-18
66. 66. Janda WM, Santos E, Stenens J, Celig D, Terrile L, Schrekkenberger PC: Unexpected isolation of Bordetella pertussis from a blood culture. Journal of Clinical Microbiology (1993) 32:2851-2853
67. 67. White JM, Fairley CK, Owen D, Matthews RC, Miller E: The effect of an accelerated immunisation schedule on pertussis in England and Wales. Communicable Disease Report Review (1996) 6:86-91
68. 68. Abbott JD, Macauley ME, Preston NW: Bacteriological diagnosis of whooping cough. Association of Clinical Pathologists. Broadsheet 105. British Medical Association, London (1982)
69. 69. Anonymous: Pertussis: adults, infants and herds. Lancet (1992) 339:526-527
70. 70. Preston NW: Prevalent serotypes of Bordetella pertussis in non-vaccinated communities. Journal of Hygiene, Cambridge (1976) 77:85-91
71. 71. Preston NW: Type-specific immunity against whooping cough. British Medical Journal (1963) 2:724-726
72. 72. Van der Zee A, Mooi F, Van Embden J, Musser J: Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. Journal of Bacteriology (1997) 179:6609-6617
73. 73. Matthews RC: The diagnosis of pertussis infections: a recurring challenge. PHLS Microbiology Digest (1997) 14:79-84
74. 74. Khattak MN, Matthews RC, Burnie JP: Is Bordetella pertussis clonal? British Medical Journal (1992) 304:813-815
75. 75. Khattak MN, Matthews RC: Genetic relatedness of Bordetella species as determined by macrorestriction digests resolved by pulsed-field gel electrophoresis. International Journal of Systematic Bacteriology (1993) 43:659-664
76. 76. Syedabubakar SN, Matthews RC, Preston NW, Owen D, Hillier V: Application of pulsed field gel electrophoresis to the 1993 epidemic of whooping cough in the UK. Epidemiology and Infection (1995) 115:101-113
77. 77. Hoppe JE, Paulus T: Comparison of three media for agar dilution susceptibility testing of Bordetella pertussis using six antibiotics. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:391-393
78. 78. Lewis K, Saubolle MA, Tenover FC, Rudinsky MF, Barbour SD, Cherry JD: Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis. Pediatric Infectious Disease Journal (1995) 14:388-391
79. 79. Korgenski EK, Daly JA: Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the intermountain west region of the United States. Journal of Clinical Microbiology (1997) 35:2989-2991
80. 80. Ewanowich CA, Chui L, Paranchych MG, Peppler MS, Marusyk RG, Albritton WL: Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by PCR methodology. Journal of Clinical Microbiology (1993) 31:1715-1725
81. 81. McNicol P, Giercke SM, Gray M, Martin D, Brodeur B, Peppler MS, Williams T, Hammond G: Evaluation and validity of a monoclonal immunofluorescent reagent for direct detection of Bordetella pertussis. Journal of Clinical Microbiology (1995) 33:2868-2871
82. 82. Halperin SA, Kasina A, Swift M: Rapid diagnosis of pertussis using the Chinese hamster ovary cell cytotoxicity assay. European Journal of Clinical Microbiology & Infectious Diseases (1995) 14:255-257
83. 83. Muller FM, Hoppe JE, Wirsing von Konig CH: Laboratory diagnosis of pertussis: state of the art in 1997. Journal of Clinical Microbiology (1997) 35:2435-2443
84. 84. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HGJ, Gaastra W, Willems RJL: Polymorphism in the Bordetella pertussis virulence factors P.69 / pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infection and Immunity (1998) 66:670-675
85. 85. Mooi FR, He Q, van Oirschot H, Mertsola J: Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infection and Immunity (1999) 67:3133-3134
86. 86. Combined Scottish Study: Diagnosis of whooping cough: comparison of serological tests with isolation of Bordetella pertussis. British Medical Journal (1970) 4:637-639
87. 87. Macaulay ME: The serological diagnosis of whooping cough. Journal of Hygiene (1979) 83:95-102
88. 88. Grimprel E, Begue P, Anjak I, Betsou F, Guiso N: Comparison of polymerase chain reaction, culture and Western immunoblot for serological diagnosis of Bordetella pertussis infection. Journal of Clinical Microbiology (1993) 31:2745-2750
89. 89. Granstrom G, Wretlind B, Salenstedt CR, Granstrom M: Evaluation of serologic assays for diagnosis of whooping cough. Journal of Clinical Microbiology (1988) 26:1818-1823
90. 90. Halperin SA, Bortolussi R, Wort AJ: Evaluation of culture, immunofluorescence and serology for the diagnosis of pertussis. Journal of Clinical Microbiology (1989) 27:752-757
91. 91. Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. Pediatric Infectious Disease Journal (1992) 11:189-193
92. 92. Aoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R: Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. Journal of Pediatrics (1996) 129:761-764
93. 93. Bace A, Zrnic T, Begovac J, Kuzmanovic N, Culig J: Short-term treatment of pertussis with azithromycin in infants and young children. European Journal of Clinical Microbiology & Infectious Diseases (1999) 18:296-298
94. 94. Sprauer MA, Cochi SL, Zell ER, Sutler RW, Mullen JR, Englender SJ, Patriarca PA: Prevention of secondary transmission of pertussis in households with early use of erythromycin. American Journal of Disease in Childhood (1992) 146:177-181
95. 95. Medical Research Council: Vaccination against whooping cough. British Medical Journal (1959) 1:994
96. 96. Department of Health: Immunisation against infectious disease 1990. Her Majesty's Stationary Office (HMSO), London (1990) pp 155-166
97. 97. Hodder SL, Mortimer EA Jr: Epidemiology of pertussis and reactions to pertussis vaccine. Epidemiologic Reviews (1992) 14:243-267
98. 98. Golden GS: Pertussis vaccine and injury to the brain. Journal of Pediatrics (1990) 116:854
99. 99. Cherry JD, Gornbein J, Heininger U, Stehr K: A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine (1998) 16:1901-1906
100. 100. Storsaeter J, Hallander HO, Gustafsson L, Olin P: Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine (1998) 16:1907-1916
101. 101. DeMelker HE, Conyn-van Spaendock MA, Rumke HC, van Wijngaarden JK, Mooi FR, Schellekens JF: Pertussis in the Netherlands: an outbreak despite high levels of immunisation with whole cell vaccine. Emerging Infectious Diseases (1997) 3:175-178
102. 102. Hewlett EL, Cherry JD: New and improved vaccines against pertussis. In: Woodrow GC, Levine MM (eds): New generation vaccines. Marcel Dekker, New York (1990) pp 231-256
103. 103. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H: Randomised, controlled trial of two-component, three-component and five-component acellular pertussis vaccine compared with whole-cell pertussis vaccine. Lancet (1997) 350:1569-1577
104. 104. Tran Minh NN, Edelman K, He Q, Viljanen MK, Arvilommi H, Mertsola J: Antibody and cell-mediated immune responses to booster immunisation with a new acellular pertussis vaccine in school children. Vaccine (1998) 16:1604-1610